Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADCOLD DS is a combination pharmaceutical product developed by Adwin Life Care, primarily indicated for the symptomatic relief of the common cold and upper respiratory tract infections in pediatric patients. It is a multi-ingredient formulation typically containing an antipyretic and analgesic (paracetamol), a nasal decongestant (phenylephrine hydrochloride), and a first-generation antihistamine (chlorpheniramine maleate). Paracetamol works by inhibiting prostaglandin synthesis in the central nervous system to alleviate fever and pain. Phenylephrine acts as a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction in the nasal passages to reduce congestion. Chlorpheniramine serves as a competitive H1 receptor antagonist, mitigating allergic symptoms such as sneezing, itching, and watery eyes. The "DS" designation typically refers to a "Double Strength" formulation, providing higher concentrations of active ingredients per dose compared to standard pediatric versions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chlorpheniramine maleate + paracetamol + phenylephrine hydrochloride.